Zurück zu den Rankings

HealthEquity, Inc. (HQY)

POSITIVE
HealthcareHealth Information ServicesUnited States

Fundamental

82

Kurs

$105.13

Marktkapitalisierung

$8.86B

Teil 1 · Was das Unternehmen wert ist

Übersicht

HealthEquity is a US administrator of tax-advantaged healthcare accounts. Its core product is the Health Savings Account (HSA), a personal account that lets an American with a high-deductible health plan set money aside for medical costs with a triple tax break: the contribution is deductible, the returns accumulate untaxed, and withdrawals for medical expenses are tax-free. Around that core it also administers complementary consumer-directed benefits (CDBs) — flexible spending accounts, health reimbursement arrangements, COBRA continuation coverage and commuter benefits. As of January 31, 2026 it administered 10.6 million HSAs holding $36.5 billion of assets, plus 7.2 million other accounts, for a total of 17.8 million accounts. It is an IRS-approved non-bank custodian, so it may legally hold members' HSA money itself rather than only servicing accounts held elsewhere. It does not sell to consumers directly: it reaches them through their employers ("Clients"), which it in turn reaches through benefits brokers and through more than 200 integrated "Network Partners" — health plans, benefits administrators and retirement recordkeepers. Its market share of HSA assets grew from 4% in December 2010 to 20% as of June 2025, and by the Devenir mid-2025 survey it was the largest HSA provider by number of accounts and the second largest by assets.

Wie das Geld verdient wird

Three streams. Service revenue is the administration fee, paid mostly per account per month by employers, health plans or the member, plus asset-based fees on invested HSA balances and fees from the healthcare marketplace. Custodial revenue is the spread the company earns on money it holds but does not own: uninvested HSA cash placed with insurance partners and with federally insured bank and credit union "Depository Partners", plus employer-held funds on deposit — HealthEquity keeps the yield and passes a lower rate to members. Interchange revenue is the merchant fee collected every time a member pays with a HealthEquity payment card. In fiscal 2026 custodial revenue was the largest of the three, and its growth came from the average annualised yield on HSA cash rising from 3.11% to 3.53% as older contracts were replaced by higher-rate ones and participation in the "Enhanced Rates" offering rose from 49% to 58% of HSA cash. The model is highly recurring: the company states that the vast majority of its accounts are opened before the fiscal year even begins.

Umsatz nach Segment

Custodial revenue48.5%

The yield HealthEquity earns on HSA cash placed with insurance company partners and with federally insured bank and credit union Depository Partners, and on employer-held funds on deposit. The counterparties paying it are financial institutions, not the members whose money it is. FY2026 revenue was $636.8 million of $1,313.4 million total.

Service revenue36.9%

Administration fees for running HSAs and complementary consumer-directed benefits, paid by employers, health plans and members, plus asset-based fees on invested HSA balances and revenue from the healthcare marketplace. FY2026 revenue was $485.0 million of $1,313.4 million total.

Interchange revenue14.6%

The fee merchants pay on each transaction when a member spends from an account using a HealthEquity physical or virtual payment card. It grows with the number of accounts and with spending per card. FY2026 revenue was $191.6 million of $1,313.4 million total.

Wettbewerbsvorteil

Skaleneffekte · Schmal

The filing describes a real scale position: 17.8 million accounts, 20% of HSA assets against 4% in 2010, first by account count and second by assets in the Devenir survey, integration with more than 200 Network Partners, and status as an IRS-approved non-bank custodian — a licence a would-be entrant has to earn and keep by meeting a net worth test. Scale also feeds acquisitions: the company buys HSA portfolios that banks treat as non-core, as with the $425 million BenefitWallet purchase in fiscal 2025, and folds them onto one platform. Being the only provider that bundles HSAs with every major complementary benefit adds friction to leaving. The limits are real too, and the company states them: its direct competitors include Fidelity, UnitedHealth's Optum and Webster Bank, which can devote more resources than HealthEquity has; Network Partners can switch to a rival or start competing directly; and roughly half of revenue is a deposit spread that depends on rates and on partner contracts rather than on anything proprietary. Hence narrow rather than wide.

Was die Nachfrage antreibt

Mäßig zyklisch

Two very different engines sit inside one company. The account business is close to defensive: fees recur monthly, accounts follow the employer benefit calendar rather than the economy, balances stay with the member across job changes and retirement, and the company says the vast majority of accounts are already open before the fiscal year begins. Its structural driver is the cost of American health insurance — the company cites the 2025 KFF survey showing average family premiums up 26% since 2020 and 53% since 2015, which pushes employers toward high-deductible plans and therefore toward HSAs, and notes that the July 2025 One Big Beautiful Bill Act extended HSA eligibility to Bronze and Catastrophic plans. The custodial half is the swing factor and is not defensive at all: it is a deposit spread, so it rises and falls with interest rates, which is why the company lists a rate decline as a separate risk. Within the year, results are seasonal — new accounts arrive in January with employers' plan years, and the cost of onboarding them lands in the third and mostly fourth fiscal quarters, before the revenue does.

Wichtigste Risiken

  • The tax advantage of the accounts could be reduced or removed — The company's first disclosed risk factor is that any diminution in, elimination of, or change in the availability of tax benefits for HSAs and other CDBs would materially adversely affect it. Its offerings consist primarily of services that exist because US tax law enables, mandates or favours them; it also states that changes in tax policy are speculative and may affect the business in ways that are hard to predict. A separate factor covers any decline in the use of HSAs or other CDBs itself.
  • Falling interest rates cut custodial income — The company discloses that a decline in interest rates would reduce its income on HSA Assets and Client-held funds and its ability to attract HSA contributions. A separate factor covers a decline in the value of invested HSA Assets, which would reduce the asset-based fees inside service revenue.
  • Failure of a partner holding members' money — Two disclosed factors concern the money HealthEquity places with others: failure to adequately place and safeguard HSA cash and Client-held funds, or the failure of any insurance company partner or Depository Partner, and separately failure to manage the liquidity of those custodial assets, could each materially and adversely affect the business, financial condition and results of operations.
  • Cyber attacks and account fraud — The company discloses that cyber attacks, including ransomware, or other privacy or data security incidents could materially adversely impact the business. It also discloses that fraudulent activity, whether involving member accounts or third-party service providers, has already led — and could continue to lead — to financial and reputational damage and could reduce the use and acceptance of its products.
  • Competitors with deeper pockets — The company discloses it may be unable to compete effectively against current and future competitors, naming among direct competitors Fidelity Investments, UnitedHealth Group's Optum and Webster Bank, which are in a position to devote more resources to developing, selling and supporting their products than HealthEquity has at its disposal.
  • Dependence on Network Partners for distribution — The company discloses that its business increasingly depends on Network Partners' willingness to partner with it; some of them hold significant regional market share, and in other regions several competing partners chase the same business, which at times prevents HealthEquity from bidding or upsets a partner it did not bid with. If those partners choose rivals, reduce the offering or stop offering its products, results, business and prospects could be materially adversely affected.
  • Regulation of the accounts, the custodian and the card — The company discloses that it is subject to extensive, complex and frequently changing federal and state law — IRS, HHS and Department of Labor rules, ERISA, HIPAA, the Advisers Act, state banking and third-party administrator laws, the Affordable Care Act and emerging AI regulation. Specific factors cover its Wyoming-regulated non-depository trust company subsidiary, the risk of losing non-bank custodian status if it fails the IRS net worth test, and changes to interchange fee laws or card network rules that could reduce revenue.
  • Acquisitions may not deliver — The company discloses that its acquisition and investment strategies may not be successful, that integration may not succeed and anticipated synergies may not be realised, and that it may need to record write-downs from future impairments of identified intangible assets and goodwill.

Kundenkonzentration

The filing states that in the fiscal years ended January 31, 2026, 2025 and 2024, no single customer accounted for more than 10% of total revenue, and it does not quantify the weight of the largest ones. The disclosed concentration is of a different kind: the company says it derives a substantial portion of revenue from serving tax-advantaged healthcare account holders, so a downturn in that single market or a change in the tax treatment of those accounts would hit the whole business at once. There is also a distribution concentration it discloses separately — access to employers runs through more than 200 Network Partners, some of which hold significant market share in their regions.

Die Argumente dafür

Buyers argue that HealthEquity sits on a structural current in American healthcare and gets paid twice for it. Employers keep shifting cost onto employees as premiums climb — the company cites the KFF survey showing average family premiums up 53% since 2015 — which pushes enrolment into high-deductible plans and therefore into HSAs, and the July 2025 One Big Beautiful Bill Act widened eligibility further. Every account added is close to permanent: it belongs to the member, survives a change of employer, and the company adds a million new HSAs from sales in a year while starting each fiscal year with most of its accounts already open. On top of the recurring fee, buyers point to the balances themselves: $36.5 billion of HSA assets on which the company earns a spread, with the average annualised yield on HSA cash rising from 3.11% to 3.53% in fiscal 2026 as older contracts roll into higher-rate ones and Enhanced Rates participation climbed from 49% to 58% of HSA cash — a repricing that continues mechanically as remaining Basic Rates contracts expire. They also argue consolidation favours the incumbent, since banks treat HSA books as non-core and sell them, as Conduent did with BenefitWallet's 616,000 accounts for $425 million, and that operating leverage is showing: fiscal 2026 net income rose 123% on 9% revenue growth.

Die Argumente dagegen

Sellers fear that nearly half the company's revenue is not a technology business at all but a deposit spread. Custodial revenue was 48.5% of fiscal 2026 revenue and carries almost no direct cost, so it is the bulk of the profit — and the company itself lists a decline in interest rates as a risk factor that would cut income on HSA Assets and Client-held funds. In the same fiscal year, the service line that represents the actual administration work grew just 1%, with the company noting that gains in accounts and invested assets were largely offset by lower average fees per account, which sellers read as price pressure in the core. They point to who that core competes with: Fidelity, Optum and Webster Bank, competitors the filing acknowledges can devote more resources than HealthEquity has. Distribution is not fully in the company's hands either — access runs through Network Partners that can switch to rivals or compete directly, as some health plans have. Above all sits legislative risk that no operating skill offsets: the entire product category exists because of a tax provision, and the company's first disclosed risk factor is that any change to it would materially hurt the business. Sellers also note the disclosed history of account fraud and cyber risk, and that growth has leaned on buying HSA portfolios — a $425 million purchase in fiscal 2025 — with the filing conceding that integration may not succeed and that goodwill and intangibles may need to be written down.

Generated on 23. August 2026 with claude-opus-5 — shared with all users

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 23. August 2026 with claude-opus-5 — shared with all users

P/E: 25.6Score: 74Market cap: $350.16B

HealthEquity's 10-K names UnitedHealth Group's Optum as a direct competitor: Optum Bank is the other large non-bank HSA custodian bidding for the same employer and health-plan accounts.

Fidelity Investments (FMR LLC)Not tracked

Cited in HealthEquity's 10-K as a retail investment firm that entered the HSA business and took significant market share, competing for the same employer-sponsored accounts and the same invested HSA balances.

Webster Financial Corporation (HSA Bank)WBS

Its HSA Bank division is one of the four largest HSA custodians in the United States and competes for the same employers, brokers and health-plan distribution channels.

WEX Inc.WEX

Its Benefits segment administers HSAs, FSAs, HRAs and COBRA for employers and health plans, the same consumer-directed benefit accounts that make up HealthEquity's CDB business.

Inspira Financial (già Millennium Trust / PayFlex)Not tracked

A privately held custodian and administrator of HSAs, FSAs and COBRA that bids for the same mid-market and large employer benefit contracts.

Bilanz & Liquidität

Umsatz

$1.34B

Letzte 12 Monate (bis 30.4.2026)

Nettogewinn

$231M

Letzte 12 Monate (bis 30.4.2026)

Freier Cashflow

$455M

Gesamtes Eigenkapital

$2.11B

Gesamtverbindlichkeiten

$1.27B

Current Ratio

3.44

Zinsdeckungsgrad

6.24

Schulden/EBITDA

2.06

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Unterbewertet

Innerer Wert

$268.06

Aktueller Kurs

$105.13

Sicherheitsmarge

+60.8%

Innerer-Wert-Spanne

$174.24 - $361.88

Bewertungsmethoden

Analyst Target:$118.53
DCF:$595.09
PE-based:$53.14
Graham Growth:$137.45
EPV:$39.77
Analystenkonsens:Starker Kauf (19B / 1H / 0S)
Letzte Gewinnüberraschung:+10.10%

Bewertungskennzahlen

P/E-Verhältnis

39.48

ROE

10.2%

P/B-Verhältnis

4.30

P/FCF

18.07

Bruttomarge

70.7%

ROIC

8.5%

Rentabilitäts-Radar

Value Creation (Economic Moat)

ROIC

8.5%

WACC

7.7%

ROIC − WACC

+0.9 pp

ROIC is roughly in line with the cost of capital — the company is barely covering its capital cost.

Fundamentalanalyse-Kriterien

Bestanden (23)

  • EPS shows upward trend
  • EPS CAGR 19.23%
  • Price CAGR 10.03%
  • ROIC 8.5%
  • Gross Margin 70.7%
  • P/FCF 18.07
  • Debt/Equity ratio
  • Operating Margin 25.6%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 10.9%
  • Revenue Growth 5Y 12.4%
  • Analyst Consensus 95% Buy
  • Earnings Surprise avg 9.6%
  • PEG Ratio 0.46
  • Earnings Quality (OCF/NI) 2.12
  • Share Dilution -1.4%
  • Net Margin Trend 17.3% vs 9.8%
  • Piotroski F-Score 9/9

Nicht bestanden (4)

  • P/B Ratio 4.30
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)

Nicht verfügbar (1)

  • Dividend Payout NaN%

Piotroski F-Score

9/9

Starke finanzielle Gesundheit

score
criteria

Gewinnqualität

2.12

Hohe Qualität: Gewinne durch Cashflow gedeckt

Aktienverwässerung

-1.4%

Aktienrückkäufe. Aktionärsfreundlich

Unternehmensführung

Führungsteam

NamePositionAlter
Mr. Scott R. Cutler J.D.CEO, President & Director55
Dr. Stephen D. Neeleman M.D.Founder & Vice Chairman57
Mr. James M. LucaniaCFO & Executive VP46
Mr. Delano Ladd J.D.Executive VP, General Counsel & Secretary44
Mr. Michael FioreExecutive VP & Chief Commercial Officer50
Mr. Richard PutnamVice President of Investor Relations-
Ms. Stacey UllrichSenior Vice President of Corporate Communications-
Mr. Steve LindsayExecutive Vice President of Sales & Relationship Management-
Mr. Brad BennionExecutive Vice President of Corporate Development & Strategy-
Mr. Mukund RamachandranChief Marketing Officer-

Prüfungsrisiko

6

Vorstandsrisiko

1

Vergütungsrisiko

1

Aktionärsrechterisiko

2

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Latest News

Recent headlines for HQY, sourced from Markets Gazette.

  • 5/28/2026NEUTRAL
    HealthEquity Q1 2027 Earnings Call: Complete Transcript

    HealthEquity Inc. has released the complete transcript for its Q1 2027 Earnings Call, dated May 28, 2026. While the transcript is now available, the provided information does not include specific financial results, forward-looking statements, or management commentary that would indicate a positive or negative market sentiment. Investors should review the full transcript for detailed insights into the company's performance and outlook.

  • 3/15/2026POSITIVE
    Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?

    Boone Capital Management has disclosed a new stake in HealthEquity Inc., a provider of cloud-based healthcare savings solutions. This initiation of a position by a significant hedge fund often signals a belief in the company's future growth prospects and undervaluation. HealthEquity serves a broad client network across the U.S., offering services that are increasingly relevant in managing healthcare costs. Investors may view this development as a positive catalyst, potentially leading to increased institutional interest and a re-evaluation of the stock's market price.

via Markets Gazette